Alterations in the fecal microbiota in patients with advanced cystic fibrosis liver disease after 6 months of elexacaftor/tezacaftor/ivacaftor

Cystic fibrosis (CF) associated liver disease (CFLD) is a significant cause of morbidity and mortality for patients for cystic fibrosis (PwCF), accounting for 2.6 % of overall mortality and the fourth leading cause of death for PwCF in the United States [1]. CFLD describes a wide spectrum of disease, ranging from elevated serum transaminases to hepatic steatosis, focal biliary cirrhosis, and advanced CF liver disease. Advanced CFLD (aCFLD) can be further categorized as multilobular cirrhosis with or without portal hypertension or noncirrhotic portal hypertension [2].

Source: Journal of Cystic Fibrosis - March 6, 2024 Category: Respiratory Medicine Authors: Jennifer T Duong, Christopher E Pope, Hillary S Hayden, Carson Miller, Stephen J Salipante, Steven M Rowe, George M Solomon, David Nichols, Lucas R Hoffman, Michael R Narkewicz, Nicole Green Tags: Original Article Source Type: research